Percentage of tumour-positive biopsy cores: An independent predictor of extraprostatic disease

Scandinavian Journal of Urology and Nephrology

Volumn 43, Issue 2, 2009, Pages 109-113

  Mortensen, Martin Mørck ^a   Mortensen, Peter S ^b   Borre, Michael ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Danish Centre for Studies in Research and Research Policy   (Denmark)

Author keywords

Biopsy cores; Prostate cancer; Screening; Staging

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BLOOD LEVEL; DISEASE SEVERITY; EXTRAPROSTATE DISEASE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSTATE DISEASE; PROSTATECTOMY; TUMOR BIOPSY; UNIVERSITY HOSPITAL;

BIOPSY, NEEDLE; DIGITAL RECTAL EXAMINATION; HUMANS; LOGISTIC MODELS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECTUM; RISK FACTORS;

EID: 61349137624     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590802670348     Document Type: Article

References (10)

1. Brasso K, Ingimarsdottir IJ, Thomassen L, Friis S, Iversen P. [Prostate cancer in Denmark 1943-2002]. Ugeskr Laeger 2007;169:129-32.
2. Varenhorst E, Garmo H, Holmberg L, Adolfsson J, Damber JE, Hellstrom M, et al. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival. Scand J Urol Nephrol 2005;39:117-23.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
4. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69: 1095-101.
5. Gancarczyk KJ, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology 2003;61:589-95.
6. Freedland SJ, Terris MK, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, et al. Preoperative model for predicting prostate specific antigen recurrence after radical prostatectomy using percent of biopsy tissue with cancer, biopsy Gleason grade and serum prostate specific antigen. J Urol 2004;171:2215-20.
7. Tarjan M, Tot T. Prediction of extracapsular extension of prostate cancer based on systematic core biopsies. Scand J Urol Nephrol 2006;40:459-64.
8. Freedland SJ, Aronson WJ, Csathy GS, Kane CJ, Amling CL, Presti JC Jr, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003;61:742-7.
9. Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, et al. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol 2003;43:6-10; Discussion.
10. Eskicorapci SY, Karabulut E, Turkeri L, Baltaci S, Cal C, Toktas G, et al. Validation of 2001 Partin tables in Turkey: a multicenter study. Eur Urol 2005;47:185-9.